Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$41.85
Change (%) Stock is Up 0.65 (1.58%)
Volume202,509
Data as of 09/19/18 11:13 a.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
Morgan Stanley Global Healthcare Conference  (Replay)
09/14/18 at 10:30 a.m. ET
Morgan Stanley Global Healthcare Conference
Friday, September 14, 2018 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Presentation
Download Documentation Corporate Presentation (August 2018)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
09/07/18GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Morgan Stanley Global Healthcare Conference in New York City on Friday, September 14 at 10:30 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, develop ... 
Printer Friendly Version
09/06/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on September 4, 2018, the compensation committee of the Company’s board of directors granted five new employees options to purchase an aggregate of 71,000 shares of the Company’s common stock with a per share exercise price of $49.50, the closing trading price on the grant date, and restricted stock units for an aggregate of 48,150 shares of the Company’s co... 
Printer Friendly Version
09/06/18GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting SCD Community During National SCD Awareness Month Livestream of Conference Will Be Available through Collaboration with Sickle Cell Warriors SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host the 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Thursday, September 13, 2018, at the Park Central ... 
Printer Friendly Version
08/23/18GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of inclacumab, a novel fully human monoclonal antibody against P-selectin. GBT plans to develop inclacumab as a treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).  Under the terms of the a... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.